Abstract
Following AAV-based gene transfer, the occurrence of adaptive immune responses specific to the vector or the transgene product is a major roadblock to successful clinical translation. These responses include antibodies against the AAV capsid, which can be neutralizing and therefore prevent the ability to repeatedly administer the vector, and CD8+ cytotoxic T lymphocytes, which can eliminate transduced cells. In addition, humans may have both humoral and cellular preexisting immunity, as a result from natural infection with parent virus or related serotypes. The need for assays to detect and measure these anti-capsid immune responses in humans and in experimental animals is profound. Here, ELISPOT, immunocapture (ELISA), and neutralization assays are explained and provided in detail. Furthermore, such techniques can readily be adapted to monitor and quantify immune responses against therapeutic transgene products encoded by the vector genome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ross, C. J., Twisk, J., Bakker, A. C., Miao, F., Verbart, D., Rip, J., Godbey, T., Dijkhuizen, P., Hermens, W. T., Kastelein, J. J., Kuivenhoven, J. A., Meulenberg, J. M., and Hayden, M. R. (2006) Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation, Hum Gene Ther 17, 487–499.
Herzog, R. W., Mount, J. D., Arruda, V. R., High, K. A., and Lothrop, C. D., Jr. (2001) Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation, Mol Ther 4, 192–200.
Gao, G., Lebherz, C., Weiner, D. J., Grant, R., Calcedo, R., McCullough, B., Bagg, A., Zhang, Y., and Wilson, J. M. (2004) Erythropoietin gene therapy leads to autoimmune anemia in macaques, Blood 103, 3300–3302.
Favre, D., Blouin, V., Provost, N., Spisek, R., Porrot, F., Bohl, D., Marme, F., Cherel, Y., Salvetti, A., Hurtrel, B., Heard, J. M., Riviere, Y., and Moullier, P. (2002) Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus, J Virol 76, 11605–11611.
Chenuaud, P., Larcher, T., Rabinowitz, J. E., Provost, N., Cherel, Y., Casadevall, N., Samulski, R. J., and Moullier, P. (2004) Autoimmune anemia in macaques following erythropoietin gene therapy, Blood 103, 3303–3304.
Niemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., and Lothrop, C. D., Jr. (2009) Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy, Blood 113, 797–806.
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., Jr., and High, K. A. (2002) Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy, Blood 99, 2670–2676.
Mingozzi, F., Liu, Y. L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., and Herzog, R. W. (2003) Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer, J Clin Invest 111, 1347–1356.
Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., Arruda, V. R., and High, K. A. (2007) Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver, Blood 110, 2334–2341.
Dobrzynski, E., Mingozzi, F., Liu, Y. L., Bendo, E., Cao, O., Wang, L., and Herzog, R. W. (2004) Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer, Blood 104, 969–977.
Dobrzynski, E., Fitzgerald, J. C., Cao, O., Mingozzi, F., Wang, L., and Herzog, R. W. (2006) Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells, Proc Natl Acad Sci U S A 103, 4592–4597.
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., and Wilson, J. M. (2009) Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses, J Infect Dis 199, 381–390.
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., and Masurier, C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus types 1, 2, 5, 6, 8 and 9 in the healthy population: implications for gene therapy using AAV vectors, Hum Gene Ther.
Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., and Pierce, G. F. (2006) Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice, Blood 107, 1810–1817.
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P. K., Nakai, H., Chew, A., Leonard, D., Wright, J. F., Lessard, R. R., Sommer, J. M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H. C., High, K. A., and Kay, M. A. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med 12, 342–347.
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., Mingozzi, F., High, K. A., and Pierce, G. F. (2006) Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy, Blood 108, 3321–3328.
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., and High, K. A. (2009) AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells, Blood 114, 2077–2086.
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C., and High, K. A. (2007) CD8(+) T-cell responses to adeno-associated virus capsid in humans, Nat Med 13, 419–422.
Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., Spencer, C., Byrne, B. J., Wilson, J. M., and Flotte, T. R. (2009) Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy, Proc Natl Acad Sci U S A 106, 16363–16368.
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., Orange, J. S., and High, K. A. (2009) Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors, J Clin Invest 119, 1688–1695.
Wang, L., Figueredo, J., Calcedo, R., Lin, J., and Wilson, J. M. (2007) Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets, Hum Gene Ther 18, 185–194.
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C., and High, K. A. (2005) Identification of mouse AAV capsid-specific CD8+ T cell epitopes, Mol Ther 12, 1023–1033.
Chen, J., Wu, Q., Yang, P., Hsu, H. C., and Mountz, J. D. (2006) Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy, Mol Ther 13, 260–269.
Xiao, W., Chirmule, N., Schnell, M. A., Tazelaar, J., Hughes, J. V., and Wilson, J. M. (2000) Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors, Mol Ther 1, 323–329.
Murphy, S. L., Li, H., Mingozzi, F., Sabatino, D. E., Hui, D. J., Edmonson, S. A., and High, K. A. (2009) Diverse IgG subclass responses to adeno-associated virus infection and vector administration, J Med Virol 81, 65–74.
Herzog, R. W., Fields, P. A., Arruda, V. R., Brubaker, J. O., Armstrong, E., McClintock, D., Bellinger, D. A., Couto, L. B., Nichols, T. C., and High, K. A. (2002) Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy, Hum Gene Ther 13, 1281–1291.
Fields, P. A., Kowalczyk, D. W., Arruda, V. R., Armstrong, E., McCleland, M. L., Hagstrom, J. N., Pasi, K. J., Ertl, H. C., Herzog, R. W., and High, K. A. (2000) Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX, Mol Ther 1, 225–235.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Martino, A.T., Herzog, R.W., Anegon, I., Adjali, O. (2012). Measuring Immune Responses to Recombinant AAV Gene Transfer. In: Snyder, R., Moullier, P. (eds) Adeno-Associated Virus. Methods in Molecular Biology, vol 807. Humana Press. https://doi.org/10.1007/978-1-61779-370-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-61779-370-7_11
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-369-1
Online ISBN: 978-1-61779-370-7
eBook Packages: Springer Protocols